Evolent Health (EVH) Tops Q3 EPS by 23c; Offers FY23 Revenue Guidance

Evolent Health (NYSE: EVH) reported Q3 EPS of $0.30, $0.23 better than the analyst estimate of $0.07. Revenue for the quarter came in at $511 million versus the consensus estimate of $509.21 million.

GUIDANCE:

Evolent Health sees FY2023 revenue of $1.95-1.97 billion, versus the consensus of $1.95 billion.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge